Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)

赛马鲁肽 杜拉鲁肽 医学 内科学 胃肠病学 2型糖尿病 内分泌学 糖尿病 艾塞那肽 利拉鲁肽
作者
Tomohiko Kimura,Yukino Katakura,Masashi Shimoda,Fumiko Kawasaki,Mizuho Yamabe,Fuminori Tatsumi,Michihiro Matsuki,Yuichiro Iwamoto,Takatoshi Anno,Yoshiro Fushimi,Shinji Kamei,Yukiko Kimura,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto,COMING study Group
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3632-3647 被引量:22
标识
DOI:10.1111/dom.15258
摘要

AIM: To compare the clinical usefulness of once-weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide at the doses approved for use in Japanese patients with type 2 diabetes. METHODS: In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial. The primary endpoint was the difference of HbA1c level between the two groups at 24 weeks. RESULTS: HbA1c level at 24 weeks was significantly lower in the semaglutide group (7.9 ± 0.5%-6.7 ± 0.5%) compared with the dulaglutide group (8.1 ± 0.6%-7.4 ± 0.8%) (p < .0001). Reduction in body mass index and visceral fat area were also more significant in the semaglutide group (p < .05, respectively). The achievement rate of HbA1c <7% was higher in the semaglutide group (p < .0001). The parameters such as low-density lipoprotein cholesterol, alanine aminotransferase and γ-glutamyl transpeptidase were decreased in the semaglutide group. Surprisingly, only semaglutide group significantly improved the apolipoprotein B/A1 ratio, which is considered a useful myocardial infarction risk index. Using computed tomography, the liver to spleen ratio was significantly elevated only in the semaglutide group. In contrast, gastrointestinal symptoms were observed in 13.2% of dulaglutide and 46.3% of semaglutide group (p < .01). The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group. CONCLUSIONS: This prospective trial showed that semaglutide has more pronounced glucose- and body mass index-lowering effects and reduces liver fat percentage and visceral fat area and that dulaglutide has less gastrointestinal symptoms and superior Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李12344完成签到,获得积分10
1秒前
研友_Z30GJ8发布了新的文献求助10
1秒前
星辰大海的应助被叶晨洋采纳,获得10
1秒前
柠檬完成签到,获得积分10
2秒前
嘻嘻哈哈的应助被bzdgbl采纳,获得10
2秒前
2秒前
2秒前
2秒前
trx发布了新的文献求助10
3秒前
时光机带哥走完成签到 ,获得积分10
3秒前
欢喜南霜发布了新的文献求助10
3秒前
丘比特的应助被Cloud采纳,获得10
5秒前
慕青的应助被标致青雪采纳,获得10
5秒前
幽默弘文发布了新的文献求助10
6秒前
秋风的应助被听话的老太采纳,获得20
6秒前
Msong发布了新的文献求助10
6秒前
ZD发布了新的文献求助10
6秒前
香蕉觅云的应助被wuzhi采纳,获得10
7秒前
7秒前
田様的应助被徐子博采纳,获得10
7秒前
molihuakai的应助被不想活了采纳,获得10
7秒前
8秒前
沈xxx发布了新的文献求助10
8秒前
佳佳发布了新的文献求助10
8秒前
坠入爱盒完成签到,获得积分10
9秒前
小龙仔123完成签到 ,获得积分10
9秒前
坚强卿完成签到,获得积分10
9秒前
11秒前
天马完成签到,获得积分10
11秒前
ding的应助被粥vbbb采纳,获得10
11秒前
111发布了新的文献求助10
11秒前
星辰大海的应助被粥vbbb采纳,获得10
12秒前
12秒前
12秒前
猫猫发布了新的文献求助10
12秒前
13秒前
13秒前
小蘑菇的应助被欢呼问寒采纳,获得30
14秒前
huhu完成签到,获得积分10
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192548
求助须知:如何正确求助?哪些是违规求助? 9579054
关于积分的说明 21863359
捐赠科研通 7792096
什么是DOI,文献DOI怎么找? 3436955
关于科研通互助平台的介绍 2560622
邀请新用户注册赠送积分活动 2483860